Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850628 | ISIN: US46625H1005 | Ticker-Symbol: CMC
Tradegate
07.11.24
11:32 Uhr
228,80 Euro
-1,35
-0,59 %
1-Jahres-Chart
JPMORGAN CHASE & CO Chart 1 Jahr
5-Tage-Chart
JPMORGAN CHASE & CO 5-Tage-Chart
RealtimeGeldBriefZeit
228,20228,4011:34
228,20228,7011:34
PR Newswire
302 Leser
Artikel bewerten:
(2)

Nium and Kinexys by J.P. Morgan (formerly Onyx by J.P. Morgan) Enhance Cross-Border Payment Accuracy with Account Validation Services in Malaysia, Thailand, and Hong Kong

Collective network intelligence is used to validate account information before initiating payments, reducing misdirected payments and fraud

SINGAPORE, Nov. 7, 2024 /PRNewswire/ -- Nium today announced an expansion to its global collaboration with Kinexys by J.P. Morgan (formerly Onyx by J.P. Morgan), with the cross-border payments leader being the first fintech company to provide data that helps validate bank account details used in international payments to Malaysia, Thailand, and Hong Kong. Nium Verify will provide data to Confirm, an application developed by Kinexys by J.P. Morgan, designed for the exchange of global account validation information. The solution is used to validate beneficiary account details in real-time, prior to payment, significantly reducing the likelihood of errors and failed payments when making cross-border transactions.

Nium_Logo

Institutions across the globe experience a high number of payment returns and fraud due to the inability to verify account information in real time prior to payment processing. This results in unnecessary fees, payment delays, and customer experience issues. Based on a market evaluation of high-value payment returns in 2020, there is an opportunity to save millions of dollars on high value payments and three to four days of payment-related delays.

Nium is providing data from Nium Verify to Liink, developed by Kinexys by J.P. Morgan's blockchain business unit, which provides scalable solutions and creates ecosystems that transform the way information, money, and assets move. Liink is the world's first bank-led, peer-to-peer network that facilitates secure and private information and capability exchange between dozens of sophisticated global institutions, such as banks, credit unions, fintechs and digital banks, among others. Built on a private, permissioned blockchain network, Liink enables participants to share information across its network, all while maintaining the three fundamental properties of information sharing: sovereignty, security and privacy.

"The additional markets for which Nium is able to provide data coverage will expand Confirm's significant global reach even further, providing incremental value to inquiring participants on the network without requiring any incremental technology uplift," said Zack Chestnut, Global Head of Business Development for Kinexys Liink and Kinexys Digital Payments. "This is in line with Confirm's goal to provide global account verification services through a single, secure network. We are excited to partner with Nium to provide additional value to our participants and make the global payments ecosystem more efficient."

Globally, Nium Verify provides real-time insight into the account beneficiaries in more than 50 markets. It applies advanced technologies to indicate in real-time whether account details are accurate. Nium introduced Verify at the Money20/20 conference in Las Vegas.

"We are excited to deepen our relationship with Kinexys by J.P. Morgan and move closer towards our shared goal of providing businesses with faster, more secure, and reliable payment experiences in the rapidly growing APAC region," said Alex Johnson, Chief Payments Officer at Nium. "This collaboration aligns with Nium's mission to simplify and streamline cross-border payments for businesses worldwide. By leveraging our account verification capabilities, we are reducing friction in global payments, creating a more efficient, secure, and compliant payments ecosystem."

For more information about Nium Verify, visit the link here.

About Nium

Nium, the leading global infrastructure for real-time cross-border payments, was founded on the mission to deliver the global payments infrastructure of tomorrow, today. With the onset of the global economy, its payments infrastructure is shaping how banks, fintechs, and businesses everywhere collect, convert, and disburse funds instantly across borders. Its payout network supports 100 currencies and spans 220+ markets, 100 of which in real-time. Funds can be disbursed to accounts, wallets, and cards and collected locally in 35 markets. Nium's growing card issuance business is already available in 34 countries. Nium holds regulatory licences and authorisations in more than 40 countries, enabling seamless onboarding, rapid integration, and compliance - independent of geography. The company is co-headquartered in San Francisco and Singapore.

Logo: https://mma.prnewswire.com/media/1678669/5010242/Nium_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/nium-and-kinexys-by-jp-morgan-formerly-onyx-by-jp-morgan-enhance-cross-border-payment-accuracy-with-account-validation-services-in-malaysia-thailand-and-hong-kong-302297618.html

© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.